Eli Lilly reports a 39% revenue jump to $24.4 billion in Q3 2026, driven by high demand for Mounjaro and Zepbound, leading the company to raise its full-year financial outlook.
Eli Lilly demonstrated robust financial growth in Q3 2026, with revenue climbing 39% to $24.4 billion. This performance was underpinned by the strong market adoption of Mounjaro and Zepbound, alongside non-recurring benefits such as $410 million in Jardiance milestones.
The growth was primarily driven by the strong sales performance of Mounjaro and Zepbound.
No, the company confirmed that no further Jardiance milestones remain after the $410 million recognized in Q3.
Eli Lilly reported a robust 39% revenue increase to $24.4 billion for the third quarter of 2026, fueled by the strong commercial performance of its flagship drugs Mounjaro and Zepbound. The company also benefited from $900 million in one-time items, including $410 million in Jardiance milestones, prompting an upward revision to its full-year financial guidance.
The 39% revenue increase was primarily driven by strong sales of the company's flagship medications, Mounjaro and Zepbound.
Yes, following the strong Q3 performance, Eli Lilly raised its full-year financial guidance.